Gyre Therapeutics (NASDAQ:GYRE) Issues Earnings Results

Gyre Therapeutics (NASDAQ:GYRE) issued its earnings results on Thursday. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.04), Zacks reports. Gyre Therapeutics had a net margin of 4.31% and a return on equity of 11.25%. The business had revenue of $37.20 million during the quarter, compared to the consensus estimate of $36.30 million.

Gyre Therapeutics Price Performance

Shares of GYRE traded down $0.25 during midday trading on Friday, hitting $7.55. The stock had a trading volume of 138,333 shares, compared to its average volume of 114,571. The firm has a market cap of $727.29 million, a price-to-earnings ratio of 755.76 and a beta of 1.97. The company has a 50 day simple moving average of $7.96 and a two-hundred day simple moving average of $7.78. Gyre Therapeutics has a twelve month low of $6.11 and a twelve month high of $12.62.

Hedge Funds Weigh In On Gyre Therapeutics

A number of large investors have recently bought and sold shares of GYRE. Bank of America Corp DE raised its position in Gyre Therapeutics by 28.8% during the second quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock worth $46,000 after acquiring an additional 1,402 shares in the last quarter. Alliancebernstein L.P. grew its position in shares of Gyre Therapeutics by 9.5% in the 3rd quarter. Alliancebernstein L.P. now owns 21,830 shares of the company’s stock valued at $163,000 after acquiring an additional 1,900 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Gyre Therapeutics by 84.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock worth $47,000 after purchasing an additional 2,961 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Gyre Therapeutics by 77.8% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock valued at $54,000 after purchasing an additional 3,244 shares during the period. Finally, Barclays PLC lifted its stake in Gyre Therapeutics by 38.3% in the 4th quarter. Barclays PLC now owns 18,531 shares of the company’s stock valued at $131,000 after purchasing an additional 5,135 shares during the last quarter. Institutional investors and hedge funds own 23.99% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Wall Street Zen lowered Gyre Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday. Weiss Ratings reissued a “sell (d)” rating on shares of Gyre Therapeutics in a research note on Thursday, January 22nd. Finally, Zacks Research raised shares of Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, November 14th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $17.00.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.